通过拯救必需的 D4R 基因来选择重组 MVA。

Baxter BioScience, Biomedical Research Center, Uferstrasse 15, 2304 Orth an der Donau, Austria.

Virol J. 2011 Dec 12;8:529. doi: 10.1186/1743-422X-8-529.

Modified vaccinia virus Ankara (MVA) has become a promising vaccine vector due to its immunogenicity and its proven safety in humans. As a general approach for stringent and rapid selection of recombinant MVA, we assessed marker rescue of the essential viral D4R gene in an engineered deletion mutant that is fully replication defective in wild-type cells. Recombinant, replicating virus was obtained by re-introduction of the deleted viral gene as a dominant selection marker into the deletion mutant.

改良安卡拉牛痘病毒（MVA）由于其免疫原性和在人类中已被证实的安全性，已成为一种很有前途的疫苗载体。作为严格和快速选择重组 MVA 的一般方法，我们评估了在一个工程缺失突变体中对必需病毒 D4R 基因进行标记拯救的方法，该突变体在野生型细胞中完全复制缺陷。通过将缺失的病毒基因作为显性选择标记重新引入缺失突变体中来获得复制的重组病毒。